SCHEMBL8290472

SCHEMBL8290472

CC(=O)c1ccc(NC(=O)/C=C/c2ccc(C)o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 1.00
SMN1; SMN2 Q16637 9/20 1.00
TP53 P04637 2/20 1.00
RAB9A P51151 7/20 0.70
NPC1 O15118 3/20 0.70
ALDH1A1 P00352 14/20 0.69
KDM4E B2RXH2 9/20 0.69
HPGD P15428 7/20 0.69
MEN1 O00255 6/20 0.67
KMT2A Q03164 6/20 0.67
LMNA P02545 4/20 0.67
ALOX12 P18054 1/20 0.67
L3MBTL1 Q9Y468 3/20 0.66
CACNA1B Q00975 1/20 0.66
APBA1 Q02410 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
PKM P14618 3/20 0.65
BLM P54132 2/20 0.60
HTT P42858 2/20 0.57
POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17417196 0.83 MAPT (0.70) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL17417197 0.83 MAPT (0.70) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL8290531 0.74 ALDH1A1 (0.68) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL19511930 0.74 LMNA (0.62) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL183203 0.73 ALDH1A1 (1.00) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL14793134 0.73 ALDH1A1 (1.00) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL2574097 0.72 NMT1 (0.69) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL2574096 0.72 NMT1 (0.69) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL196167 0.71 SMN1; SMN2 (0.69) MAPTSMN1; SMN2TP53RAB9ANPC1
SCHEMBL196166 0.71 SMN1; SMN2 (0.69) MAPTSMN1; SMN2TP53RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
WO-2005037257-A2 NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES IMTM GMBH (DE) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases DNPEP, PREP, ANPEP MAPT 1400/4885SMN1; SMN2 2829/4885TP53 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.